Lessons learned from a clinical trial

Circulation

Volumn 110, Issue 23, 2004, Pages 3610-3614

  Armstrong, Paul W ^a   Newby, L Kristin ^b   Granger, Christopher B ^b   Lee, Kerry L ^b   Simes, R John ^c   Van De Werf, Frans ^d   White, Harvey D ^e   Califf, Robert M ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL   (Australia)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Biomedical research; Ethics, research; Multicenter studies; Trials, clinical

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOTRAFIBAN; ORBOFIBAN; PYRIDINE DERIVATIVE; SIBRAFIBAN; THIENOPYRIDINE; TICLOPIDINE; UNCLASSIFIED DRUG; XEMILOFIBAN;

CLINICAL TRIAL; DRUG COST; DRUG SAFETY; EXPERIENCE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HUMAN; INTERPERSONAL COMMUNICATION; LEARNING; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; THROMBOSIS; WELFARE;

ASPIRIN; BIOMEDICAL RESEARCH; CORONARY DISEASE; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HUMAN EXPERIMENTATION; HUMANS; INTERDISCIPLINARY COMMUNICATION; MULTICENTER STUDIES; OXIMES; PIPERIDINES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROFESSIONAL STAFF COMMITTEES; QUALITY OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; RECURRENCE;

EID: 10044228370     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000148680.83392.50     Document Type: Review

References (28)

1. Angell M. The pharmaceutical industry: to whom it is accountable? N Engl J Med. 2000;342:1902-1904. Editorial.
2. SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomized trial. Lancet. 2000;355:337-345.
3. Second SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation. 2001;103:1727-1733.
4. Califf RM, Peterson ED, Gibbons RJ, et al. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol. 2002;40:1895-1901.
5. Cannon CP, McCabe CH, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 Trial. Circulation. 1998;97:340-349.
6. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
7. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet. 1996;348:1329-1339.
8. EPIC Investigators. Use of a monochromal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
9. PURSUIT Investigators. Inhibition of glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
10. Reimann JD, Modi NB, Novotny W. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin. J Clin Pharmacol. 2000;40:488-495.
11. Newby LK, for the SYMPHONY Steering Committee. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the Sibrafiban Versus Aspirin to Yield Maximum Protection From Ischemic Heart Events Post-Acute Coronary Syndromes (SYMPHONY) Trial. Am Heart J. 1999;138:210-218.
12. O'Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. N Engl J Med. 2000;342:1316-1324.
13. Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;102:149-156.
14. McGuire DK, Newby LK. Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial. J Thromb Thrombolysis. 2000;10:111-119.
15. Newby LK, Califf RM, White HD, et al. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med. 2002;112:647-658.
16. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283:2701-2711.
17. Armstrong PW, Furberg C. Clinical trial data and safety monitoring boards: the search for a constitution. Circulation. 1995;91:901-904.
18. Califf RM, Morse MA, Wittes J, et al. Toward protecting the safety of participants in clinical trials. Control Clin Trials. 2003;24:256-271.
19. Topol EJ, Easton D, Harrington RA, et al. for the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399-406.
20. Topol EJ, Califf RM, Van de Werf F, et al, for the VIGOUR Group. Perspectives on large-scale cardiovascular clinical trials for the new millennium. Circulation. 1997;95:1072-1082.
21. Morse MA, Califf RM, Sugarman J. Monitoring and ensuring safety during clinical research. JAMA. 2001;285:1201-1205.
22. Moher D, Schulz KF, Altman D, for the CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285:1987-1991.
23. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201-206.
24. Huth EJ. Guidelines on authorship of medical papers. Ann Intern Med. 1986;104:269-274.
25. Schulman KA, Seils DM, Timbie JW, et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med. 2002;347:1335-1341.
26. Peter K, Schwarz M, Ylanne J, et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors. Blood. 1998;92:3240-3249.
27. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
28. Steinhubl SR, Berger PB, Mann JT, et al, for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.